Building on the knowledge that autophagy is involved in both glucose metabolism and the maintenance of malignancy in lung tumors, their findings suggest that the concurrent inhibition of autophagy represents a promising strategy to overcome drug resistance in NSCLC cells treated with LDHA inhibitors [34,35]. The gene discussed is LDHA; the disease is non-small cell lung carcinoma.